AUTHOR=Masood Aetsam Bin , Batool Sajida , Bhatti Sajid Nazir , Ali Asad , Valko Marian , Jomova Klaudia , Kuca Kamil 

TITLE=Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study

JOURNAL=Frontiers in Immunology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1202098

DOI=10.3389/fimmu.2023.1202098

ISSN=1664-3224

ABSTRACT=Glioblastoma multiform (GBM) is the most aggressive, malignant and therapy-resistant tumor of the brain. Blockade therapy targeting programmed cell death protein 1 (PD-1)/programmed death ligand (PD-L1) axis is currently under investigation for the clinical management of the GBM. This study has quantified the plasma levels of PD-L1 as biomarker for clinical management of GBM. A cohort (n=128) of Pakistani adult glioblastoma patients together with age and sex-matched healthy controls was used for quantification of pre-surgery levels of plasma PD-L1. PD-L1 protein and mRNA were measured by PD-L1 platinum ELISA assay and quantitative real-time PCR respectively. Receiver operating characteristic (ROC) curve analysis was used to compute area under curve (AUC) for specificity and sensitivity analyses. The Kaplan-Meier survival analysis was employed to compute overall survival. PD-L1 protein and mRNA were significantly higher in GBM compared to the healthy controls (p<0.0001). Mean PD-L1 concentration for the GBM was found to be 48.98±2.290pg/ml compared to 27.63±1.281pg/ml for controls. Gene expression analysis showed statistically significant upregulation (p<0.0001) of PD-L1 in blood of GBM compared to healthy controls. Plasma PD-L1 showed AUC of 0.840 (p<0.0001; 95% CI = 0.7716 to 0.9090) where a cutoff value higher than 46pg/ml demonstrated 100% specificity and 57.81% sensitivity. Higher presurgery levels of PD-L1 were found to be associated with overall poor survival (p<0.0001; HR (logrank) = 0.08; 95% CI = 0.04 to 0.15). Age, gender and ethnic background were not found to be associated with plasma PD-L1 levels. The study concludes that blood-based measurements of PD-L1 in GBM can be a promising prognostic marker and therapeutic target besides a rapid and relatively non-invasive screening tool for routine clinical management. Future work extending the analysis to larger cohorts through multi-center collaborations involving pre-treatment and post-treatment groups is required to fully explore the usefulness of circulating PD-L1 for effective clinical applications.